Xilio Therapeutics, Inc.
XLO
$8.46
-$0.05-0.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 179.13% | -16.17% | -13.78% | 22.89% | 25.84% |
| Total Depreciation and Amortization | -14.10% | -10.53% | -14.38% | 12.19% | -16.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,309.29% | 947.14% | 143.88% | -16.26% | -22.05% |
| Change in Net Operating Assets | 291.55% | -1,022.57% | -108.45% | 808.72% | -261.32% |
| Cash from Operations | 85.89% | -27.96% | -172.56% | 375.93% | -5.44% |
| Capital Expenditure | -1,483.33% | 100.00% | -1,809.52% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1,483.33% | 100.00% | -1,809.52% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | 910.72% | -100.00% | -99.78% | 12.16% | 15,088.89% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 337.28% | -9,400.00% | 136.30% | 406.50% | 601.96% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 666.57% | -29.93% | -18.74% | 453.88% | 60.42% |